Recent Finacing
Recent Raise
OncoImmune is a clinical-stage biopharmaceutical company developing CD24Fc and other CD24–Siglec pathway immunotherapies, conducting Phase III trials for COVID-19 and post-transplant GvHD and advancing IO mAbs and cancer vaccines.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
